Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

Burkina Faso Resources

Fact sheet [English] [Français] 
Infographic [English] [Français]

Related Posts

  • TCV co-administered with routine immunizations at 9-months

    Confirmed! TCV can be co-administered with routine measles-rubella AND yellow fever vaccines at 9 months

  • Une nouvelle étude du Burkina Faso confirme que les vaccins conjugués contre la typhoïde (Vi-TCV) sont sûrs, immunogènes et peuvent être co-administrés

  • A new study from Burkina Faso further confirms typhoid conjugate vaccines (TCV) are safe, immunogenic and can be co-administered

Related Publications

  • Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomised controlled phase 2 trial

  • Pathogens causing acute febrile illness among children and adolescents in Burkina Faso, Madagascar and Sudan

  • Pathogens causing acute febrile illness among children and adolescents in Burkina Faso, Madagascar and Sudan

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2175 K Street, NW, Suite 400
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top